Skip to main navigation
Skip to search
Skip to main content
WashU Medicine Research Profiles Home
Help & FAQ
Link opens in a new tab
Search content at WashU Medicine Research Profiles
Home
Profiles
Departments, Divisions and Centers
Research output
Primary resistance to PD-1 blockade mediated by JAK1/2 mutations
Daniel Sanghoon Shin
,
Jesse M. Zaretsky
, Helena Escuin-Ordinas
, Angel Garcia-Diaz
, Siwen Hu-Lieskovan
, Anusha Kalbasi
, Catherine S. Grasso
, Willy Hugo
, Salemiz Sandoval
, Davis Y. Torrejon
, Nicolaos Palaskas
, Gabriel Abril-Rodriguez
, Giulia Parisi
, Ariel Azhdam
, Bartosz Chmielowski
, Grace Cherry
, Elizabeth Seja
, Beata Berent-Maoz
, I. Peter Shintaku
, Dung T. Le
Drew M. Pardoll, Luis A. Diaz, Paul C. Tumeh, Thomas G. Graeber, Roger S. Lo, Begoña Comin-Anduix, Antoni Ribas
Show 7 others
Show less
Section of Medical Oncology
Siteman Cancer Center
Research output
:
Contribution to journal
›
Article
›
peer-review
1119
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Primary resistance to PD-1 blockade mediated by JAK1/2 mutations'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Primary Resistance
100%
Janus Kinase 1 (JAK1)
100%
PD-1 Blockade
100%
Interferon-γ
42%
Anti-PD-1 Therapy
42%
PD-L1 Expression
42%
Gain-of-function mutation
28%
Genetic Mechanism
28%
PD-1 Blockade Therapy
28%
Tumor
14%
Acquired Resistance
14%
Loss Function
14%
Cancer Genome Atlas
14%
Cancer Cells
14%
Adverse Outcomes
14%
Functional Outcome
14%
Interferon Receptor
14%
Colon Cancer
14%
Programmed Death-ligand 1 (PD-L1)
14%
Tumor Biopsy
14%
Melanoma
14%
Stimulator of Interferon Genes (STING)
14%
Mismatch Repair
14%
Human Melanoma Cells
14%
Inactivating mutation
14%
Mutational Load
14%
Gamma Exposure
14%
Medicine and Dentistry
Programmed Death-Ligand 1
100%
Gamma Interferon
75%
Loss of Function Mutation
50%
Interferon
25%
Cancer Cell
25%
Tumor Biopsy
25%
Somatics
25%
Adverse Outcome
25%
Tumor
25%
The Cancer Genome Atlas
25%
Programmed Death 1 Receptor
25%
Melanoma Cell Line
25%
DNA Mismatch Repair
25%
Colon Carcinoma
25%
Mutational Load
25%
Gamma Interferon Receptor
25%
Melanoma
25%
Biochemistry, Genetics and Molecular Biology
PD-L1
100%
Interferon Gamma
75%
Loss of Function Mutation
50%
Genetic Mechanism
50%
Cancer Cell
25%
Synapsin I
25%
DNA Mismatch Repair
25%
Colon
25%
Mutational Load
25%
Interferon-Stimulated Gene
25%
Interferon-Gamma Receptor
25%
Pharmacology, Toxicology and Pharmaceutical Science
Gamma Interferon
100%
Malignant Neoplasm
66%
Melanoma
66%
Neoplasm
33%
Interferon
33%
Adverse Outcome
33%
Colon Carcinoma
33%
Programmed Death 1 Receptor
33%
Gamma Interferon Receptor
33%
Immunology and Microbiology
Programmed Death-Ligand 1
100%
Interferon Gamma
75%
Loss of Function Mutation
50%
Cancer Cell
25%
Colon
25%
Interferon-Gamma Receptor
25%
Interferon-Stimulated Gene
25%
Melanoma Cell Line
25%
Mismatch Repair
25%
Programmed Death 1 Receptor
25%
Mutational Load
25%